TrialClinical drug investigation2022

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA.

Yelena Ionova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.